Decrease (-) Restore Default Increase (+)

Clinical Trials

Topic   Cancer - Breast Cancer
Title   ALLIANCE 011502: A Randomized Phase III Double Blinded Placebo Controlled Trial of Aspirin as Adjuvant Therapy for Node Positive HER2 Negative Breast Cancer: The ABC Trial
Summary   The aim of this study is to compare the good and bad effects of using aspirin after the usual chemotherapy, surgery and/or radiation for treatment of early stage node-positive HER2 negative breast cancer. Aspirin is approved by the Food and Drug Administration (FDA), but is not approved for the purpose of lowering the risk of breast cancer returning or improving survival. This study will evaluate whether patients taking aspirin have a lower rate of breast cancer recurrence.
Description   Patients will be randomized to receive 300 mg aspirin daily for 5 years or placebo daily for 5 years. The study also involves completing questionnaires that are designed to evaluate lifestyle factors that may be related to inflammation. Patients will be followed for a total of 10 years.
IRB Number   1076289
Inclusion/Notes   To be eligible to participate in this study, patients must meet several criteria including but not limited to the following: 19 - 69 years of age; regular aspirin or NSAID use is allowed if stopped 1 year prior to study entry and throughout the study; patients are enrolled within 1 year of their breast cancer diagnosis.
Status   Open
Start Date   08/01/2017
Principal Name   Nina D’Abreo, MD
Contact Name   Johanna Lee, RN
Email   JLee8@nyuwinthrop.org
Fax   516-663-1871
Current Trial Type   Interventional
Phone   516-663-1237
Alternate Phone   516-663-8391